Science
& Research
Dermatology represents our core scientific focus
Research & Development
Our research activities aim to explore device-based approaches designed to address dermatological conditions through controlled and scientifically validated mechanisms. All development programs are conducted in accordance with:
• Applicable European Medical Device Regulation (EU 2017/745)
• Good Clinical Practice (GCP)
• Internal quality management procedures
Clinical development framework
Where applicable, clinical investigations are conducted:
• Under approved Clinical Investigation Plans (CIP)
• With ethics committee oversight
• With appropriate regulatory authority notifications
• Under documented quality control procedures
Clinical data are generated, collected, processed, analyzed, and reported
in compliance with regulatory requirements.
Pipeline overview
R&D Pharma’s development pipeline includes investigational dermatology
MDC-75
Regulatory Status:
Under regulatory review
Medical Device Class IIa
MDC-75 is currently under regulatory review. The device is not CE marked and is not commercially available in the European Union.
MDC-85
Regulatory Status:
Clinical Investigation Phase
MDC-85 is an investigational device currently being evaluated in a clinical investigation. The clinical investigation aims to assess safety and clinical performance in patients diagnosed with superficial basal cell carcinoma (sBCC), in accordance with applicable regulatory requirements.
Important Information
The products described above on this website are either under regulatory review or under clinical investigation.
They are not CE marked and are not commercially available in the European Union. Information provided on this website is intended for corporate and scientific informational purposes only and does not constitute promotional material.
No claims regarding safety or efficacy are made outside the context of approved regulatory documentation.